# Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

> **NCT04132674** · PHASE4 · UNKNOWN · sponsor: **Vancouver Infectious Diseases Centre** · enrollment: 40 (estimated)

## Conditions studied

- Human Immunodeficiency Virus I Infection
- Drug Use

## Interventions

- **DRUG:** Bictegravir/emtricitabine/tenofovir alafenamide

## Key facts

- **NCT ID:** NCT04132674
- **Lead sponsor:** Vancouver Infectious Diseases Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-26
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04132674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04132674, "Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04132674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*